Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · December 03, 2019

The Impact of New Systemic Therapies on Survival and Time on Hormonal Treatment in HR+/HER2− MBC

Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Cancer
The Impact of New Systemic Therapies on Survival and Time on Hormonal Treatment in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Population-Based Study in British Columbia From 2003 To 2013
Cancer 2019 Nov 21;[EPub Ahead of Print], D Le, C Speers, L Thompson, L Gondara, A Nichol, C Lohrisch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading